SLU-PP-332 has no human dosing data, so this page computes what can honestly be computed: amounts per container, what each costs, and the concentration if you dissolve a powder vial. Mechanism, the rodent evidence and the full test record sit on the SLU-PP-332 compound guide.
A 10 mg vial of SLU-PP-332 divided into 1 mg amounts gives 10 amounts per vial. At the median tracked price of $11.00 per mg, each 1 mg amount is about $11.00 of compound; at the lowest tracked $5.90 per mg it is about $5.90. If you dissolve the same 10 mg vial in 1 mL of solvent the solution is 10 mg/mL, so 0.1 mL carries 1 mg. SLU-PP-332 has no human dosing data, so the 1 mg amount above is an arithmetic reference we divided by — it is not a recommended dose, and this page does not have one to give you.
Prices are the median and lowest tracked per milligram as of 2 September 2026. There are no syringe units on this page: no injectable route for SLU-PP-332 appears in any of our sources.
SLU-PP-332 (also designated SR9861) is a synthetic small-molecule pan-agonist of the estrogen-related receptors ERRα, ERRβ and ERRγ, most potent at ERRα (EC₅₀ ≈ 98 nM). It is not a peptide — chemically it is a naphthalene–hydrazone small molecule, C18H14N2O2, 290.32 g/mol — and despite being marketed by many vendors as an “exercise-mimetic peptide”, it has never been administered to humans in a controlled study. All published efficacy data come from rodent models.
What this page can compute is container arithmetic: a 10 mg vial split into 1 mg amounts is 10 amounts, about $11.00 each at the median tracked price. What it cannot compute is how much you should take, because nothing in our sources says. The arithmetic is deterministic; the amount input is yours, not ours.
There is no dose table anywhere on this platform because no dose figure exists to tabulate. Every published finding comes from rodent models; the compound has never completed a human clinical trial and has no active clinical-development programme. That means no approved dose, no trial arm, no titration ladder and no maintenance amount — not even the “convention” tier that research compounds with a following usually accumulate. The table below prints that absence with its evidence level, in the shape a real dose table would take.
| Route | Amount | Frequency | Duration | Evidence level |
|---|---|---|---|---|
| Oral (capsule or tablet) | — | — | — | Sold this way, but a route with no established absorption profile for this compound |
| Oral (weighed powder) | — | — | — | Sold this way; no amount, no frequency, no measurement protocol in our sources |
| Injection, any route | — | — | — | No injectable route is named anywhere in our sources |
| Any human amount | — | — | — | None exists — never administered to humans in a controlled study |
| Any regulator-approved amount | — | — | — | None exists — not approved for human use anywhere in the world |
| Rodent mg/kg from the 2023 Burris work | — | — | — | Present in the literature but not reproduced on any of our source pages. A rodent mg/kg does not convert to a human amount and is not printed here as if it did |
The dose column is empty on every row. SLU-PP-332 is sold as capsules, tablets and lyophilised powder; it has never been given to a human in a controlled study; it is not approved anywhere; and no injectable route appears in our sources. Any milligram figure you have seen attached to it came from somewhere other than evidence.
What the evidence base does contain: a 2023 ACS Chemical Biology study from the Burris laboratory showing SLU-PP-332 triggered an ERRα-dependent acute aerobic-exercise-like response and enhanced exercise capacity in mice — with no human data before or since. Related rodent work reported reduced fat mass and improved metabolic parameters in diet-induced obese mice, attributed to increased fatty-acid oxidation and mitochondrial output. Because it has never been given to humans in a controlled study, there is no established human side-effect profile, no known safe dose and no long-term safety data.
The general method — why an amount needs a concentration and a container before it means anything — is at how to calculate peptide doses.
Powder vials are tracked from 0.5 mg to 10 mg, and the arithmetic for turning one into a solution is the same as for any powder: concentration equals container milligrams divided by solvent millilitres. A 10 mg vial in 1 mL is 10 mg/mL, so 0.1 mL carries 1 mg.
| Container | In 0.5 mL | In 1 mL | In 2 mL |
|---|---|---|---|
| 0.5 mg | 1 mg/mL → 0.1 mg per 0.1 mL | 0.5 mg/mL → 0.05 mg per 0.1 mL | 0.25 mg/mL → 0.025 mg per 0.1 mL |
| 1 mg | 2 mg/mL → 0.2 mg per 0.1 mL | 1 mg/mL → 0.1 mg per 0.1 mL | 0.5 mg/mL → 0.05 mg per 0.1 mL |
| 5 mg | 10 mg/mL → 1 mg per 0.1 mL | 5 mg/mL → 0.5 mg per 0.1 mL | 2.5 mg/mL → 0.25 mg per 0.1 mL |
| 10 mg (default) | 20 mg/mL → 2 mg per 0.1 mL | 10 mg/mL → 1 mg per 0.1 mL | 5 mg/mL → 0.5 mg per 0.1 mL |
A 10 mg vial dissolved in 1 mL is 10 mg/mL and carries 1 mg in each 0.1 mL; the same vial in 2 mL is 5 mg/mL and carries 0.5 mg. A 0.5 mg vial in 1 mL is 0.5 mg/mL — twenty times weaker per volume than the 10 mg vial at the same solvent volume, which is why the container size matters more than the volume you pick. A volume quoted without a concentration cannot be used; the vial still holds the same compound in every case.
Read that table as measurement resolution, not as a protocol. The smallest tracked container, 0.5 mg, in 1 mL of solvent gives 0.05 mg in a tenth of a millilitre. At that scale an error of a hundredth of a millilitre is a 10% error in compound. Our sources name no diluent, no diluent volume and no solubility figure for SLU-PP-332, and it is a small molecule rather than a peptide, so the bacteriostatic-water conventions that apply to lyophilised peptides are not established for it — those are covered separately, for compounds where a diluent is established, in the bacteriostatic water guide.
SLU-PP-332 has no reconstitution procedure on this platform. The compound page gives no diluent, no diluent volume, no dissolution time, no storage temperature and no in-use period for it, and none of our source pages carries a stability figure. That is a genuine gap, printed here rather than filled with a borrowed peptide procedure — a peptide's 2–8 °C, 28-day convention is not transferable to a naphthalene–hydrazone small molecule without a source.
| Step | Status |
|---|---|
| Step 1 — diluent choice | Unknown — no source page names a diluent for SLU-PP-332 |
| Step 2 — dissolution method and time | Unknown — no source page describes it |
| Step 3 — storage temperature and in-use period | Unknown — no source page gives one |
The compound guide records SLU-PP-332 being sold as capsules, tablets and lyophilised powder. Our price layer currently tracks only lyophilised powder vials, from 0.5 mg to 10 mg — no capsule or tablet offer appears in it. So the container sizes in this calculator are powder-vial sizes, and if you hold capsules or tablets, the per-container arithmetic here applies only once you know the milligram strength printed on your own product. The general procedure for powder containers, where one is established, is at reconstituting peptides step by step.
A container lasts as many amounts as its milligram content divided by the amount you take — and this page cannot convert that into weeks, because no frequency exists in our sources either. The table counts amounts, not weeks. The column headings are arithmetic divisors, not doses: they are the labelled quantities that appear on the compound page's own lab-test table (0.25 mg, 1 mg, 5 mg) plus the two round intermediates. You choose the amount; we have none to suggest.
| Container | At 0.25 mg | At 0.5 mg | At 1 mg | At 2 mg | At 5 mg |
|---|---|---|---|---|---|
| 0.5 mg | 2 | 1 | 0.5 | — | — |
| 1 mg | 4 | 2 | 1 | 0.5 | — |
| 5 mg | 20 | 10 | 5 | 2.5 | 1 |
| 10 mg (default) | 40 | 20 | 10 | 5 | 2 |
A 10 mg container divided into 1 mg amounts gives about 10 amounts. A 5 mg container divided into 1 mg amounts gives about 5. A 10 mg container divided into 0.25 mg amounts gives about 40. A 0.5 mg container divided into 1 mg amounts does not contain a full amount at all. Solvent volume changes nothing about any of it: it changes the volume you measure, never the compound in the container.
SLU-PP-332 ranks first of the 64 compounds in the Purity Index at 99.87, as of September 2026 — on six tests from three labs, the thinnest record of any compound at the top of that index. First place on six tests. The Purity Index applies a five-test minimum, which SLU-PP-332 clears by one, and no test in the record falls inside the 90-day recency window — so the index has no fresh weight to apply to it. Treat the rank as a real but thin signal. The tests establish that the two vendors covered are selling the correct molecule at close to the stated quantity. They say nothing about efficacy, dosing or safety, because nothing does.
Six tests from three labs are in the recency-weighted Purity Index; four are printed in the table on the compound page (both as of September 2026). The compound page's average across its four is 99.82% HPLC purity, tier Excellent, across 2 verified vendors.
| Date | Shop | Purity | Labelled → tested | Endotoxins | Lab |
|---|---|---|---|---|---|
| 22 Jul 2026 | glowaminos peptides | 99.83% | 1 mg → 1.06 mg (+6%) | — | ILS Laboratories |
| 15 Jun 2026 | myoasislabs peptides | 99.90% | 5 mg → 5.61 mg (+12.2%) | — | Bioviridian |
| 19 Apr 2026 | offline peptides | 99.61% | 5 mg → 5.62 mg (+12.4%) | — | freedomdiagnosticstesting.com |
| 17 Mar 2026 | glowaminos peptides | 99.95% | 0.25 mg → 0.261 mg (+4.4%) | Pass | freedomdiagnosticstesting.com |
All four tested containers came in over their label — by +4.4%, +6%, +12.2% and +12.4%, a mean overage of +8.75% across the four. Every amounts-per-container figure above is therefore a floor, not a ceiling, and every milligram you measure out of one of these containers is slightly more compound than the label implies.
| Labelled amount | At the smallest observed overage (+4.4%) | At the largest observed overage (+12.4%) |
|---|---|---|
| 0.25 mg | 0.261 mg | 0.281 mg |
| 0.5 mg | 0.522 mg | 0.562 mg |
| 1 mg | 1.044 mg | 1.124 mg |
| 5 mg | 5.22 mg | 5.62 mg |
| 10 mg | 10.44 mg | 11.24 mg |
The 0.25 mg → 0.261 mg and 5 mg → 5.62 mg rows are the measured results themselves; the rest is the same two percentages applied to the other tracked container sizes. Four tests is not a fill-variance distribution — it is four data points that all happen to point the same way, and a fifth container could sit under its label. Why label mass and delivered mass diverge in general: why 10 mg isn't 10 mg. Individual certificates: SLU-PP-332 lab test records.
The median tracked price is $11.00 per mg and the lowest tracked is $5.90 per mg, on a 10 mg vial, across 13 shops in stock and 43 identified listings. At the median a 1 mg amount is about $11.00 of compound and a 10 mg vial about $110.00. Prices were last checked on 2 September 2026 — a same-day fetch, so these are fresh.
A milligram of SLU-PP-332 bought in a 0.5–1 mg vial costs a median $121.43; the same milligram bought in a 5–10 mg vial costs a median $10.50. That is not a discount, it is the fixed cost of a vial, a freeze-drying run, a label, a lab test and a shipment being spread across more or less compound.
| Field | Value (as of 2 September 2026) |
|---|---|
| Median, all sizes | $11.00/mg |
| Lowest tracked | $5.90/mg — 10 mg vial |
| Shops in stock | 13 |
| Listings identified | 43 |
| Vial price range | $30.00–$159.99 across 0.5 mg–10 mg |
| Band medians | 0.5–1 mg: $121.43/mg (lowest $90.00) · 5–10 mg: $10.50/mg (lowest $5.90) |
| Product form tracked | Lyophilised powder vials only |
Cost is amount mg × $/mg. At the $11.00/mg median: 0.25 mg = $2.75; 0.5 mg = $5.50; 1 mg = $11.00; 5 mg = $55.00; 10 mg = $110.00. At the $5.90/mg lowest tracked: 1 mg = $5.90; 10 mg = $59.00. These are the cost of a quantity of compound, not the cost of a dose — this page has no dose.
These figures exclude shipping, taxes and customs charges; coupon codes and bulk tiers; multi-vial kits; and email-only or account-required pricing. They are the lowest tracked price, not the lowest payable price. Thirty-three retailers are known to sell SLU-PP-332; two of them have an independent lab test on file from the past year. The price figures above span shops that have never had this compound tested. Full offers table and container-size bands: SLU-PP-332 price per milligram.
SLU-PP-332 is an ERR agonist — an exercise mimetic acting on the estrogen-related receptors — which is a different mechanism from every compound it sits next to in the weight-loss and metabolic category. Those are incretin and amylin agonists that act on appetite and glucose handling. The practical difference for a calculator is that all of them have human trial data and dose figures and SLU-PP-332 has neither, and the difference in test volume is three orders of magnitude.
| Compound | Mechanism | Avg purity | Tests |
|---|---|---|---|
| SLU-PP-332 | Pan-ERR (ERRα/β/γ) agonist — exercise mimetic | 99.82% | 4 |
| Retatrutide | GLP-1 / GIP / glucagon triple agonist | 99.68% | 1,187 |
| Tirzepatide | GLP-1 / GIP dual agonist | 99.75% | 942 |
| Semaglutide | GLP-1 receptor agonist | 99.67% | 439 |
| MOTS-C | Mitochondrial-derived metabolic peptide | 99.44% | 525 |
| Cagrilintide | Long-acting amylin receptor agonist | 99.62% | 262 |
The purity percentages are averages over very different sample sizes — four tests for SLU-PP-332 against 1,187 for retatrutide — so a higher average here is not a stronger result. The mechanisms are not comparable either: SLU-PP-332 is the only compound in the table with no human data of any kind. In the compound page's own words, it is “an ERR-driven exercise mimetic, a mechanism distinct from the appetite- and metabolism-focused compounds it is often shelved alongside like 5-Amino-1MQ, AICAR, and MOTS-C. Unlike those, SLU-PP-332 has no human data at all.” The category and its members: weight-loss and metabolic peptides.
SLU-PP-332 is not approved for human use anywhere in the world and it has no active clinical-development programme of the kind that leads to regulatory approval, as of July 2026. It exists as a research chemical and chemical probe sold by laboratory-reagent suppliers and gray-market vendors, with no prescription pathway and research-use-only status. In most jurisdictions it can be purchased as a research chemical for laboratory use, but it is not approved for human consumption anywhere; buyers are responsible for verifying local rules. Country-by-country: regulatory status by country guide.
There is no answer to give. SLU-PP-332 has never been administered to humans in a controlled study, so no human dosing data, no safe dose and no side-effect profile exist. It is not approved for human use anywhere. This calculator divides a container into amounts you specify; it does not know, and cannot suggest, what that amount should be.
No. It is a synthetic small-molecule pan-agonist of the ERRα, ERRβ and ERRγ receptors — a naphthalene–hydrazone, C18H14N2O2, 290.32 g/mol, with no amino-acid chain. It is not an anabolic steroid either, since it does not act on androgen receptors. Vendors marketing it as an “exercise-mimetic peptide” are using the word incorrectly.
Our sources set no diluent and no volume for this compound, so the choice is yours and there is no convention to fall back on. The arithmetic is fixed: a 10 mg vial in 1 mL is 10 mg/mL, which puts 1 mg in each 0.1 mL; the same vial in 2 mL is 5 mg/mL. Smaller containers give poorer measurement resolution.
Our sources name oral forms only — capsules, tablets and lyophilised powder — and note that oral bioavailability has been reported as poor in research settings, so the route most vendors sell has no established absorption profile. No injectable route for SLU-PP-332 appears anywhere in our sources, which is why this page prints no syringe units.
No. The rank is first of 64 compounds at an index value of 99.87, but it rests on six tests from three labs — barely past the five-test minimum, with nothing inside the 90-day recency window. Retatrutide's average sits on more than a thousand tests. Treat a first-place rank on six tests as a thin signal.
Median $11.00 per mg across 13 shops in stock, lowest tracked $5.90 per mg on a 10 mg vial, as of 2 September 2026. Container size dominates: the 0.5–1 mg band medians $121.43 per mg against $10.50 in the 5–10 mg band. Those figures exclude shipping, taxes, coupons, bulk tiers and kits.